MedEsthetics July/August 2017
Physicians share their most popular and effective combination treatment regimens.

Patients seeking skin rejuvenation procedures typically present with a variety of concerns ranging from skin laxity to brown spots, visible vascularity, and fine lines and wrinkles. Delivering optimal outcomes often requires the use of multiple treatment modalities. This has led physicians to embrace combination treatments that enable them to treat several signs of aging in one treatment session, saving...

Articles

MedEsthetics July/August 2017

Patients seeking skin rejuvenation procedures typically present with a variety of...

Preparing the Skin for Laser Resurfacing

The value of pretreatment skincare protocols for ablative laser procedures has been...

MedEsthetics Cover Profile July/August 2017

When Wendy Roberts, MD, applied to Sarah Lawrence College in New York, a career in...

Understanding Laser Contracts

Laser treatments have become a staple of the medical aes­thetics industry. More than 2...

Products

Biopelle antiaging eye treatment

The Tensage Growth Factor + Stem Cell Dual Eye Care Kit from Biopelle is a...

Safer sclerotherapy injections

The ergonomic SyrEase Syringe Adaptor from Syris Scientific allows providers...

Titanium and zinc oxide sun protection.

Epionce Daily Shield Lotion Tinted SPF 50 provides all skin types—including...

Antiaging Skin Care

Induction Therapies P.R.R. Protein Rich Retinol 1.0%, 4.0% and 8.0% feature...

Blogs

Facebook Ad Leads
By Angela (Miller) Hamilton, Facebook Marketing Expert at ReachLocal With more than 1.71 billion active users on Facebook, social media advertising is an important way for medspas and medical practices to reach local consumers online. Most facilties have a company page and perhaps purchase a few...
Addressing Employee Tardiness
By Paul Edwards, CEO of CEDR HR Solutions There’s nothing more maddening than knowing your patients are due to arrive at your door at any moment, but because one or more of your employees STILL hasn’t shown up for work, you won’t be able to take the patients back right away. Despite the many...
Sientra Acquires Miramar Labs, maker of miraDry

Medical aesthetics company Sientra has acquired Miramar Labs for $20 million in upfront cash, plus contractual rights for potential contingent payments of up to $14 million in cash upon the achievement of certain milestones. The acquisition brings the miraDry system, the only FDA-cleared device to reduce underarm sweat, odor and permanently reduce hair of all colors, to Sientra’s product portfolio.

“We are extremely excited to complete the acquisition of Miramar Labs, which is a significant milestone for Sientra and continues our progress toward building a diversified global aesthetic company,” said Jeffrey M. Nugent, chairman and CEO of Sientra. “The miraDry procedure addresses a very large and underpenetrated market in the minimally invasive, lifestyle aesthetics category. We are confident that we can work with the Miramar team to accelerate their already growing business.”

Image copyright Getty Images

Allergan Acquires Regenica Line With Plans To Expand Histogen Growth Factor Technology

Allergan has acquired the Regenica growth factor-based skincare line, and will market the line’s proprietary multipotent cell-conditioned media, which was developed by regenerative medicine company Histogen. Allergan plans to incorporate the technology, known as Multipotent Resignaling Complex (MRCx), in future products under the SkinMedica portfolio.

MRCx is made up of soluble cell-signaling proteins and growth factors that support the body’s epidermal stem cells. Through Histogen’s technology process, which mimics the embryonic environment including conditions of low oxygen and suspension, cells are triggered to become multipotent, and naturally produce these proteins associated with skin renewal.

“Histogen has developed a next-generation regenerative cell technology, harnessing the power of growth factors and stem-cell signaling molecules for skin rejuvenation that complements Allergan’s flagship growth factor technology—TNS,” said Rahul Mehta, PhD, vice president of research and development at SkinMedica, an Allergan Company. “In addition to the Regenica product line, we are looking forward to collaborating with Histogen and leveraging their science to further bolster SkinMedica’s commitment to evidence-based...

Sebacia Announces $36 Million Financing to Advance Acne Microparticle Treatment

Sebacia announced that it has completed a $20 million Series D financing to complete a U.S. pivotal trial of its proprietary microparticle treatment for moderate to severe acne.

The company's gold and silica microparticles are specially designed to be activated by the light from commonly used hair removal lasers and are placed in a suspension designed to penetrate the sebaceous follicles. When exposed to a laser pulse, they create a focused photothermal effect in the sebaceous gland and follicle to reduce the activity level of the gland and the inflammatory lesions that cause acne. The treatment is intended to be a simple, physician-guided, in-office procedure that could provide an alternative to existing therapies, such as oral antibiotics and isotretinoin.

With the new funding from Versant Ventures, Domain Associates, Accuitive Medical Ventures, Partners Healthcare Innovation Fund, Salem Partners and other undisclosed investors, Sebacia intends to complete the U.S. pivotal trial with expected results reporting by mid-2018, and submission and FDA response expected by the end of 2018. Additionally, the company plans to expand its worldwide patent estate, which includes the seminal selective photothermalysis...

Biologic Therapy Dupixent (Dupilumab) Approved For Atopic Dermatitis

The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) Injection from Regeneron Pharmaceuticals, and Sanofi for the treatment of adults with moderate-to-severe atopic dermatitis (AD).


Dupixent is a human monoclonal antibody that is designed to specifically inhibit overactive signaling of two key proteins, IL-4 and IL-13, which are believed to be major drivers of the persistent underlying inflammation in AD. It comes in a pre-filled syringe and can be self-administered as a subcutaneous injection every other week after an initial loading dose and can be used... more »

AAD Commends FDA for Indoor Tanning Restrictions

The American Academy of Dermatology (AAD) applauds the U.S. Food and Drug Administration (FDA) for proposing new regulations governing indoor tanning, including an age restriction for minors under the age of 18 as well as a risk-acknowledgement form that all adults must sign before using indoor tanning devices.


According to the AAD, statistics show that millions of people tan indoors annually and the risk of developing melanoma increases by 59% for individuals exposed to UV radiation from indoor tanning—the risk increases with each use. If the FDA’s proposed rule becomes final,... more »

ASDS Honored With 14 MarCom Awards

The American Society for Dermatologic Surgery (ASDS) and American Society for Dermatologic Surgery Association (ASDSA) were recognized with 14 awards—including three Platinums—in the 2015 MarCom Awards.


The MarCom Awards competition is administered and judged by the Association of Marketing and Communication Professionals, selecting winners “whose work serves as a benchmark for the industry.” The 2015 competition received about 6,500 entries representing more than a dozen countries.


The Platinum Award—MarCom’s top honor—was presented to ASDS in three categories: Currents... more »